» Articles » PMID: 25165691

Medical Treatments for Endometriosis-associated Pelvic Pain

Overview
Journal Biomed Res Int
Publisher Wiley
Date 2014 Aug 29
PMID 25165691
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

The main sequelae of endometriosis are represented by infertility and chronic pelvic pain. Chronic pelvic pain causes disability and distress with a very high economic impact. In the last decades, an impressive amount of pharmacological agents have been tested for the treatment of endometriosis-associated pelvic pain. However, only a few of these have been introduced into clinical practice. Following the results of the controlled studies available, to date, the first-line treatment for endometriosis associated pain is still represented by oral contraceptives used continuously. Progestins represent an acceptable alternative. In women with rectovaginal lesions or colorectal endometriosis, norethisterone acetate at low dosage should be preferred. GnRH analogues may be used as second-line treatment, but significant side effects should be taken into account. Nonsteroidal anti-inflammatory drugs are widely used, but there is inconclusive evidence for their efficacy in relieving endometriosis-associated pelvic pain. Other agents such as GnRH antagonist, aromatase inhibitors, immunomodulators, selective progesterone receptor modulators, and histone deacetylase inhibitors seem to be very promising, but there is not enough evidence to support their introduction into routine clinical practice. Some other agents, such as peroxisome proliferator activated receptors-γ ligands, antiangiogenic agents, and melatonin have been proven to be efficacious in animal studies, but they have not yet been tested in clinical studies.

Citing Articles

MR Relaxometry for Discriminating Malignant Ovarian Cystic Tumors: A Prospective Multicenter Cohort Study.

Kawahara N, Kobayashi H, Maehana T, Iwai K, Yamada Y, Kawaguchi R Diagnostics (Basel). 2024; 14(11).

PMID: 38893596 PMC: 11172376. DOI: 10.3390/diagnostics14111069.


Horizons in Endometriosis: Proceedings of the Montreux Reproductive Summit, 14-15 July 2023.

Vallee A, Saridogan E, Petraglia F, Keckstein J, Polyzos N, Wyns C Facts Views Vis Obgyn. 2024; 16(16 Suppl 1):1-32.

PMID: 38603778 PMC: 11317919. DOI: 10.52054/FVVO.16.s1.011.


Flavonoids Quercetin and Kaempferol Are NR4A1 Antagonists and Suppress Endometriosis in Female Mice.

Zhang L, Mohankumar K, Martin G, Mariyam F, Park Y, Han S Endocrinology. 2023; 164(10).

PMID: 37652054 PMC: 10502789. DOI: 10.1210/endocr/bqad133.


Progesterone Resistance in Endometriosis: Current Evidence and Putative Mechanisms.

Zhang P, Wang G Int J Mol Sci. 2023; 24(8).

PMID: 37108154 PMC: 10138736. DOI: 10.3390/ijms24086992.


Current Updates on the Role of Microbiome in Endometriosis: A Narrative Review.

Ser H, Au Yong S, Shafiee M, Mokhtar N, Ali R Microorganisms. 2023; 11(2).

PMID: 36838325 PMC: 9962481. DOI: 10.3390/microorganisms11020360.


References
1.
Lu D, Song H, Shi G . Anti-TNF-α treatment for pelvic pain associated with endometriosis. Cochrane Database Syst Rev. 2013; (3):CD008088. PMC: 11366413. DOI: 10.1002/14651858.CD008088.pub3. View

2.
Lu D, Song H, Li Y, Clarke J, Shi G . Pentoxifylline for endometriosis. Cochrane Database Syst Rev. 2012; 1:CD007677. DOI: 10.1002/14651858.CD007677.pub3. View

3.
Koc O, Gunduz B, Topcuoglu A, Bugdayci G, Yilmaz F, Duran B . Effects of pinealectomy and melatonin supplementation on endometrial explants in a rat model. Eur J Obstet Gynecol Reprod Biol. 2010; 153(1):72-6. DOI: 10.1016/j.ejogrb.2010.06.012. View

4.
Menakaya U, Infante F, Condous G . Consensus on current management of endometriosis. Hum Reprod. 2013; 28(11):3162-3. DOI: 10.1093/humrep/det346. View

5.
Creus M, Fabregues F, Carmona F, Del Pino M, Manau D, Balasch J . Combined laparoscopic surgery and pentoxifylline therapy for treatment of endometriosis-associated infertility: a preliminary trial. Hum Reprod. 2008; 23(8):1910-6. DOI: 10.1093/humrep/den167. View